Clinical Trials Search at Vanderbilt-Ingram Cancer Center
RELIEVE- HF- Reducing Lung Congestion Symptoms using the V-Wave Shunt in Advance Heart Failure
Not Available
III
Punnoose, Lynn
NCT03499236
CRE-CHF0003
Open-Label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years with Haemophilia A or B with or without Inhibitors
Benign Hematologic
Benign Hematologic
Benign Hematologic
III
Wheeler, Allison
VICCNCBH21108
VANISH 2- Ventricular Tachycardia Antiarrhythmics or Ablation in Structural Heart Disease 2
Not Available
III
Kanagasundram, Arvindh
CRE-CHF0001
SOS-AMI - Protocol ID-07-076A301 Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI)
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
Not Available
III
Defilippis, Andrew
CRE-GEN0002
DEFINE-HT - DevelopmEnt of non-invasive cell-Free DNA to supplant INvasivE biopsy in Heart Transplantation
Not Available
III
Schlendorf, Kelly
CRE-CHF0010
OCEANIC-AF - A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
Not Available
III
Montgomery, Jay
CRE-ARR0018
A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension
Not Available
III
Not Available
NCT02910414
CRE-INT0003
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
Not Available
III
Esbenshade, Adam
NCT04576117
COGACNS1931
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Breast
Breast
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study
assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in
participants with stage I to III TNBC with residual invasive disease in the breast and/or
axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in
participants with stage I to III TNBC with residual invasive disease in the breast and/or
axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
Breast
III
Reid, Sonya
NCT05629585
VICC-DTBRE23074